Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 73

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 73
---
 or pancreas who have received no more than
two prior lines of therapy.

On December 14, 2023, Aadi announced results from a planned interim analysis on the first third of patients
participating in the PRECISION1 trial, following which Aadi experienced a 56% drop in its stock price to $2.34 per share. Following such announcement, Aadi’s board of directors and management regularly discussed the continued progress of the
PRECISION1 trial and related risks and uncertainties; the potential range of outcomes for the PRECISION1 trial; the business case for FYARRO beyond the PRECISION1 trial, including in EEC and NETs; and alternate options for value realization from
FYARRO, including a potential sale of the asset. During this time, Aadi’s board of directors and management also regularly discussed strategic opportunities for the company separate from FYARRO, including the potential acquisition or in-licensing of new drug programs, which discussions and related process are described in further detail under “Background of the PIPE Financing and the License Agreement” in the PIPE Financing
Proposal.

On May 3, 2024, Aadi signed an engagement letter with Leerink Partners to serve as Aadi’s financial advisor in connection with its
comprehensive assessment of strategic options, including those related to a potential sale of FYARRO.

- 48 -

On July 15 and July 16, 2024, at the direction of Aadi, Leerink Partners reached out to 28 companies,
including Bidder B, Bidder C, Bidder D, Bidder E, Bidder F, and Bidder G among other parties), of which 23 participated in introductory calls, 13 signed nondisclosure agreements (of which 10 opted to participate in management meetings) and received
virtual data room access to conduct commercial and scientific due diligence on FYARRO, including Bidder A, Bidder B, Bidder C, Bidder D, Bidder E, Bidder F, and Bidder G.

On July 26, 2024, representatives of Leerink Partners and Bidder F met via videoconference to discuss a potential transaction involving FYARRO.

On August 8, 2024, representatives of Aadi and Bidder B met via videoconference to discuss the FYARRO commercial business and Bidder B’s initial due
diligence questions.

On August 14, 2024, representatives of Leerink Partners and Bidder F met via video